Identification of chebulinic acid as potent natural inhibitor of M. tuberculosis DNA gyrase and molecular insights into its binding mode of action

Drug resistant tuberculosis has threatened all the advances that have been made in TB control at the global stage in the last few decades. DNA gyrase enzymes are an excellent target for antibacterial drug discovery as they are involved in essential functions like DNA replication. Here we report, a successful application of high throughput virtual screening (HTVS) to identify an inhibitor of Mycobacterium DNA gyrase targeting the wild type and the most prevalent three double mutants of quinolone resistant DNA gyrase namely A90V+D94G, A74S+D94G and A90V+S91P. HTVS of 179.299 compounds gave five compounds with significant binding affinity. Extra presicion (XP) docking and MD simulations gave a clear view of their interaction pattern. Among them, chebulinic acid (CA), a phytocompound obtained from Terminalia chebula was the most potent inhibitor with significantly high XP docking score, -14.63, -16.46, -15.94 and -15.11 against wild type and three variants respectively. Simulation studies for a period of 16 ns indicated stable DNA gyrA-CA complex formation. This stable binding would result in inhibition of the enzyme by two mechanisms. Firstly, binding of CA causes displacement of catalytic Tyr129 away from its target DNA-phosphate molecule from 1.6 Å to 3.8-7.3 Å and secondly, by causing steric hindrance to the binding of DNA strand at DNA binding site of enzyme. The combined effect would result in loss of cleavage and religation activity of enzyme leading to bactericidal effect on tuberculosis. This phytocompound displays desirable quality for carrying forward as a lead compound for anti-tuberculosis drug development. The results presented here are solely based on computations and need to be validated experimentally in order to assert the proposed mechanism of action.

[1]  Zhongfa Liu,et al.  Triphala and Its Active Constituent Chebulinic Acid Are Natural Inhibitors of Vascular Endothelial Growth Factor-A Mediated Angiogenesis , 2012, PloS one.

[2]  M. Hui,et al.  Multiplex PCR Amplimer Conformation Analysis for Rapid Detection of gyrA Mutations in Fluoroquinolone-Resistant Mycobacterium tuberculosis Clinical Isolates , 2004, Antimicrobial Agents and Chemotherapy.

[3]  M. Baliga Triphala, Ayurvedic formulation for treating and preventing cancer: a review. , 2010, Journal of alternative and complementary medicine.

[4]  T. Darden,et al.  A smooth particle mesh Ewald method , 1995 .

[5]  Abhinav Grover,et al.  Structural insights into mode of actions of novel natural Mycobacterium protein tyrosine phosphatase B inhibitors , 2014, BMC Genomics.

[6]  V. Jarlier,et al.  Novel Gyrase Mutations in Quinolone-Resistant and -Hypersusceptible Clinical Isolates of Mycobacterium tuberculosis: Functional Analysis of Mutant Enzymes , 2006, Antimicrobial Agents and Chemotherapy.

[7]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[8]  J. Farrar,et al.  Beijing Genotype of Mycobacterium tuberculosis Is Significantly Associated with High-Level Fluoroquinolone Resistance in Vietnam , 2008, Antimicrobial Agents and Chemotherapy.

[9]  Jack Snoeyink,et al.  Nucleic Acids Research Advance Access published April 22, 2007 MolProbity: all-atom contacts and structure validation for proteins and nucleic acids , 2007 .

[10]  F. Brossier,et al.  Treatment failure in a case of extensively drug-resistant tuberculosis associated with selection of a GyrB mutant causing fluoroquinolone resistance , 2007, European Journal of Clinical Microbiology & Infectious Diseases.

[11]  J M Thornton,et al.  LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. , 1995, Protein engineering.

[12]  Jesús S. Dehesa,et al.  Insight into the informational-structure behavior of the Diels-Alder reaction of cyclopentadiene and maleic anhydride , 2014, Journal of Molecular Modeling.

[13]  K. Mdluli,et al.  Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. , 2007, Infectious disorders drug targets.

[14]  Alexandra Aubry,et al.  First functional characterization of a singly expressed bacterial type II topoisomerase: the enzyme from Mycobacterium tuberculosis. , 2006, Biochemical and biophysical research communications.

[15]  J. Dhanjal,et al.  Novel Natural Structure Corrector of ApoE4 for Checking Alzheimer's Disease: Benefits from High Throughput Screening and Molecular Dynamics Simulations , 2013, BioMed research international.

[16]  D. Hooper,et al.  Fluoroquinolone antimicrobial agents. , 1991, Clinical microbiology reviews.

[17]  Hongma Sun,et al.  Pharmacophore-based virtual screening. , 2008, Current medicinal chemistry.

[18]  I. Laponogov,et al.  Structural insight into the quinolone–DNA cleavage complex of type IIA topoisomerases , 2009, Nature Structural &Molecular Biology.

[19]  S. Srivastava,et al.  Triphala inhibits both in vitro and in vivo xenograft growth of pancreatic tumor cells by inducing apoptosis , 2008, BMC Cancer.

[20]  Sukriti Goyal,et al.  Mechanistic insights into mode of actions of novel oligopeptidase B inhibitors for combating leishmaniasis , 2014, Journal of Molecular Modeling.

[21]  J. Berger,et al.  DNA topoisomerases: harnessing and constraining energy to govern chromosome topology , 2008, Quarterly Reviews of Biophysics.

[22]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[23]  Matthew P. Repasky,et al.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.

[24]  Gaetano T Montelione,et al.  Evaluating protein structures determined by structural genomics consortia , 2006, Proteins.

[25]  B. Barrell,et al.  Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence , 1998, Nature.

[26]  R. Colwell,et al.  Antibacterial activity of black myrobalan (Terminalia chebula Retz) against Helicobacter pylori. , 2001, International journal of antimicrobial agents.

[27]  R. Friesner,et al.  Evaluation and Reparametrization of the OPLS-AA Force Field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides† , 2001 .

[28]  G. Deep,et al.  Chemopreventive potential of Triphala (a composite Indian drug) on benzo(a)pyrene induced forestomach tumorigenesis in murine tumor model system. , 2005, Journal of experimental & clinical cancer research : CR.

[29]  H. Hiasa,et al.  DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities. , 1998, Biochimica et biophysica acta.

[30]  J. Farrar,et al.  Fluoroquinolone resistance detection in Mycobacterium tuberculosis with locked nucleic acid probe real-time PCR. , 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[31]  Woody Sherman,et al.  Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments , 2013, Journal of Computer-Aided Molecular Design.

[32]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[33]  Richard M. Jackson,et al.  Q-SiteFinder: an energy-based method for the prediction of protein-ligand binding sites , 2005, Bioinform..

[34]  W. L. Jorgensen,et al.  Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .

[35]  J. Denholm The most recent report from the World Health Organization found that, worldwide, approximately 5% of new tuberculosis cases are caused by multidrug-resistant strains (MDR TB). , 2010, Journal of travel medicine.

[36]  M. Delarue,et al.  Structural Insights into the Quinolone Resistance Mechanism of Mycobacterium tuberculosis DNA Gyrase , 2010, PloS one.

[37]  Ying Zhang,et al.  Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates. , 2008, International journal of antimicrobial agents.

[38]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[39]  J. Champoux DNA topoisomerases: structure, function, and mechanism. , 2001, Annual review of biochemistry.

[40]  I. Sugawara,et al.  Emergence of Ofloxacin Resistance in Mycobacterium tuberculosis Clinical Isolates from China as Determined by gyrA Mutation Analysis Using Denaturing High-Pressure Liquid Chromatography and DNA Sequencing , 2006, Journal of Clinical Microbiology.

[41]  G. Alangaden,et al.  Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients , 1995, Antimicrobial agents and chemotherapy.

[42]  Heena Dhiman,et al.  Resisting resistant Mycobacterium tuberculosis naturally: mechanistic insights into the inhibition of the parasite's sole signal peptidase Leader peptidase B. , 2013, Biochemical and biophysical research communications.

[43]  P. Lahorkar,et al.  Development of a RP-HPLC Method for Analysis of Triphala Curna and its Applicability to Test Variations in Triphala Curna Preparations , 2009, Indian journal of pharmaceutical sciences.

[44]  J. Musser,et al.  Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis. , 1996, The Journal of infectious diseases.

[45]  D. Singh,et al.  High-performance liquid chromatography as a tool for the chemical standardisation of Triphala--an Ayurvedic formulation. , 2008, Phytochemical analysis : PCA.